Literature DB >> 19796270

Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications.

Colleen Delaney1, Jonathan A Gutman, Frederick R Appelbaum.   

Abstract

Growing evidence supports the efficacy of cord blood transplantation (CBT) to treat patients with haematological malignancies, and the number of CBTs is rapidly increasing. Herein, we review considerations regarding conditioning regimens for CBT, the impact of double unit transplantation on CBT outcomes, and data regarding infectious complications following CBT.

Entities:  

Mesh：

Year:  2009        PMID： 19796270     DOI： 10.1111/j.1365-2141.2009.07782.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  24 in total

Review 1.  Cord blood stem cells for hematopoietic transplantation.

Authors:  Anfisa Stanevsky; Avichai Shimoni; Ronit Yerushalmi; Arnon Nagler
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 2.  Allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Jacopo Peccatori; Fabio Ciceri
Journal:  Haematologica       Date:  2010-06       Impact factor: 9.941

Review 3.  Hematopoietic stem cell transplantation for MDS.

Authors:  Matthias Bartenstein; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 4.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

5.  Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy.

Authors:  Vanderson Rocha; Stephen Spellman; Mei-Jie Zhang; Annalisa Ruggeri; Duncan Purtill; Colleen Brady; Lee Ann Baxter-Lowe; Etienne Baudoux; Paola Bergamaschi; Robert Chow; Brian Freed; Gesine Koegler; Joanne Kurtzberg; Jerome Larghero; Lucilla Lecchi; Arnon Nagler; Cristina Navarrette; Vinod Prasad; Fabienne Pouthier; Thomas Price; Voravit Ratanatharathorn; Jon J van Rood; Mary M Horowitz; Eliane Gluckman; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-17       Impact factor: 5.742

6.  Towards responsible cord blood banking models.

Authors:  P Rebulla; L Lecchi
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

7.  Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation.

Authors:  Victor E Mulanovich; Ying Jiang; Marcos de Lima; Elizabeth J Shpall; Richard E Champlin; Stefan O Ciurea
Journal:  Am J Blood Res       Date:  2011-06-07

8.  Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.

Authors:  Archana Thakur; Carly Sorenson; Oxana Norkina; Dana Schalk; Voravit Ratanatharathorn; Lawrence G Lum
Journal:  Transfusion       Date:  2011-07-11       Impact factor: 3.157

9.  Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.

Authors:  Yachiyo Kuwatsuka; Yoshiko Atsuta; Mary M Horowitz; Jiro Inagaki; Junya Kanda; Koji Kato; Katsuyoshi Koh; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-10       Impact factor: 5.742

10.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.

Authors:  Andromachi Scaradavou; Claudio G Brunstein; Mary Eapen; Jennifer Le-Rademacher; Juliet N Barker; Nelson Chao; Corey Cutler; Colleen Delaney; Fangyu Kan; Luis Isola; Chatchada Karanes; Mary J Laughlin; John E Wagner; Elizabeth J Shpall
Journal:  Blood       Date:  2012-12-09       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.